


Amendments to the Specification:

On Page 1, on the first line following the title, please add:

This application is filed pursuant to 35 U.S.C. § 371 as a United States National Phase Application of International Application No. PCT/US2005/012337 filed April 12, 2005, which claims priority from US 60/563,285 filed April 16, 2004 and US 60/605,288 filed August 27, 2004.

On Page 14, lines 13 – 26, replace the existing paragraph with the following:

In one embodiment, the compound of formula I is a compound of formula I^a



or a salt, solvate, or physiologically functional derivative thereof, wherein

Q₃ is A¹ when Q₂ is A² and Q₃ is A² when Q₂ is A¹;

wherein

A¹ is hydrogen, halogen, C₁₋₃ alkyl, and

A² is the group defined by $-(Z)_m-(Z^1)-(Z^2)$, wherein

Z is CH₂ and m is 0, 1, 2, or 3;


Z¹ is S(O)₂, S(O), or C(O); and

Z² is C₁₋₄ alkyl, or NR³R⁴; and

R^3 and R^4 are each independently selected from hydrogen, or C_{1-4} alkyl.

On Page 14, lines 27 – 28, and Page 15, lines 1- 4, replace the existing paragraph with the following:

In a preferred embodiment, the compound of formula I is a compound of formula I^b



or a salt, solvate or physiological functional derivative thereof.